Rohto Pharmaceutical
4527.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥140.8bn | ¥136.6bn | ¥128.9bn | ¥115.4bn | ¥101.2bn | ¥101.0bn |
| Operating income | ¥20.5bn | ¥20.0bn | ¥21.4bn | ¥18.6bn | ¥16.7bn | ¥13.0bn |
| Ordinary income | ¥32.4bn | ¥22.7bn | ¥26.7bn | ¥22.5bn | ¥17.5bn | ¥12.6bn |
| Total assets | ¥253.2bn | ¥232.7bn | ¥208.6bn | ¥191.9bn | ¥172.6bn | ¥153.3bn |
| Net assets / equity | ¥179.2bn | ¥159.3bn | ¥154.3bn | ¥136.6bn | ¥122.9bn | ¥114.9bn |
| EPS (basic) | ¥110.12 | ¥82.79 | ¥87.54 | ¥72.62 | ¥57.14r | ¥39.1r |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 6
| Period | Form | Figures |
|---|---|---|
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 52 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 76 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 50 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 52 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 76 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 50 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| America | ¥21.6bn | ¥1.7bn |
| Asia | ¥125.3bn | ¥15.0bn |
| Europe | ¥23.9bn | ¥1.0bn |
| Japan | ¥169.3bn | ¥22.1bn |
| Other segments | ¥3.6bn | ¥383m |
| Adjustments & eliminations | — | ¥846m |
| Total | ¥340.1bn | ¥39.9bn |
| Total | ¥343.7bn | ¥40.3bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.